国际肝病采访W. Graham Cooksley教授

采访提纲：

1，In one of your paper， you have mentioned that selecting patients for treatment and knowing when to treat them is as important as knowing which medicine to treat them with. So what do you mean when you say that? Does it have any special requests on clinical treatment? 在您的一篇文章里曾提到过，选择合适的患者在恰当的时候进行治疗与选择何种药物治疗一样重要。这里您指的是什么？对临床治疗有什么特别的要求么？

2，In interferon treatment， some experts have proposed increasing the dosage of ribavirin， so can improve treatment response， how do you think this， if we should increasing， how many? 在干扰素治疗方案中，有些专家提出加大利巴韦林的用量，这样可以提高治疗应答率，您如何看待这个问题，如果要加大剂量，加多少合适？

3，Liver transplantation is now more and more used in clinical practice， and HBV reinfection usually occurs after the operation， so what is the progress of prophylaxis of HBV reinfection after liver transplantation? What are the difference about the anti-virus in pre-transplant and post-transplant in HBV patient? 肝移植越来越频繁的应用于临床，但是移植后患者经常发生HBV再感染，预防肝移植术后乙肝病毒再感染有什么进展？慢性乙肝患者肝移植前后抗病毒治疗措施有何不同？

4，One of your main researches is interferon on HCV patients， we know that some clinical trials have proved that interferon is better than nucleoside/ nucleoside. No matter HBeAg positive or negative， even in some ’difficult-to-treat’ hepatitis B infection， interferon could demonstrate some effect. So how do you think about interferon and nucleoside/ nucleoside in clinical use？我们了解到您对干扰素治疗HCV有很深入的研究，有些临床研究已经证明干扰素的疗效优于核苷类似物，不管是HBeAg阳性还是阴性者，甚至是在一些难治性HBV感染者中也表现出一定的疗效，那我们应该怎么样看待干扰素和核苷类似物在临床应用中的地位？